Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation have announced a collaboration focused on developing a novel treatment for amyotrophic lateral sclerosis (ALS). The deal, potentially valued at up to $480 million, centers on Dewpoint's experimental medicine designed to address the underlying causes of ALS by targeting biomolecular condensates.
Collaboration Details
Under the agreement, Dewpoint grants Mitsubishi Tanabe Pharma exclusive rights to license the drug upon reaching certain near-term research and development milestones. If Mitsubishi Tanabe exercises its option to license the program, it will assume responsibility for clinical development and commercialization. In return, Dewpoint receives an upfront payment and is eligible for milestone payments and tiered royalties, potentially totaling $480 million.
Masao Nawano, head of Mitsubishi Tanabe's research division, stated, "ALS remains a critical area of unmet medical needs and [Mitsubishi Tanabe] is committed to addressing it. Together with Dewpoint, we have the potential to deliver meaningful innovations to patients and families affected by this devastating condition."
Targeting Biomolecular Condensates for ALS Treatment
Dewpoint's approach focuses on modulating biomolecular condensates, clusters of molecules within cells that play a role in cell regulation. Dysfunction of these condensates has been implicated in diseases like ALS. Specifically, Dewpoint's drug aims to break up abnormal accumulations of the TDP-43 protein, which is essential for RNA processing. When TDP-43 malfunctions or is deficient in nerve cells, it can contribute to the development of ALS.
ALS Treatment Landscape and Unmet Needs
ALS is a progressive neurodegenerative disease with limited treatment options. Mitsubishi Tanabe already markets Radicava (edaravone), one of the few FDA-approved drugs for ALS. However, its clinical benefits are considered modest, and administration can be burdensome, particularly with the intravenous formulation. Patients with ALS typically survive only two to five years after diagnosis, highlighting the urgent need for more effective therapies.
Dewpoint's Strategy and Previous Partnerships
Founded in 2019, Dewpoint Therapeutics is pioneering the development of drugs that target biomolecular condensates. While other companies like Faze Medicines have explored this approach, Dewpoint has continued to attract significant investment and collaborations. Previously, Dewpoint had established partnerships with Bayer, Merck & Co., Pfizer and Novo Nordisk, although some of these alliances have reportedly been discontinued.
